These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 16439121

  • 1. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
    Provins L, Christophe B, Danhaive P, Dulieu J, Durieu V, Gillard M, Lebon F, Lengelé S, Quéré L, van Keulen B.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1834-9. PubMed ID: 16439121
    [Abstract] [Full Text] [Related]

  • 2. Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives.
    Provins L, Christophe B, Danhaive P, Dulieu J, Gillard M, Quéré L, Stebbins K.
    Bioorg Med Chem Lett; 2007 Jun 01; 17(11):3077-80. PubMed ID: 17398090
    [Abstract] [Full Text] [Related]

  • 3. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
    Tait A, Luppi A, Avallone R, Baraldi M.
    Farmaco; 2005 Aug 01; 60(8):653-63. PubMed ID: 15963514
    [Abstract] [Full Text] [Related]

  • 4. Alkyne-quinuclidine derivatives as potent and selective muscarinic antagonists for the treatment of COPD.
    Starck JP, Provins L, Christophe B, Gillard M, Jadot S, Lo Brutto P, Quéré L, Talaga P, Guyaux M.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2675-8. PubMed ID: 18359633
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M, Bommelé KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ, Timmerman H.
    J Med Chem; 2003 May 08; 46(10):2008-16. PubMed ID: 12723963
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D, Mastracchio A, Perrier H, Dubé D, Gallant M, Lacombe P, Deschênes D, Roy B, Scheigetz J, Bateman K, Li C, Trimble LA, Day S, Chauret N, Nicoll-Griffith DA, Silva JM, Huang Z, Laliberté F, Liu S, Ethier D, Pon D, Muise E, Boulet L, Chan CC, Styhler A, Charleson S, Mancini J, Masson P, Claveau D, Nicholson D, Turner M, Young RN, Girard Y.
    Bioorg Med Chem Lett; 2005 Dec 01; 15(23):5241-6. PubMed ID: 16168647
    [Abstract] [Full Text] [Related]

  • 9. Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
    Pitts WJ, Vaccaro W, Huynh T, Leftheris K, Roberge JY, Barbosa J, Guo J, Brown B, Watson A, Donaldson K, Starling GC, Kiener PA, Poss MA, Dodd JH, Barrish JC.
    Bioorg Med Chem Lett; 2004 Jun 07; 14(11):2955-8. PubMed ID: 15125967
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides.
    Anderson AJ, Nicholson JM, Bakare O, Butcher RJ, Wilson TL, Scott KR.
    Bioorg Med Chem; 2006 Feb 15; 14(4):997-1006. PubMed ID: 16219468
    [Abstract] [Full Text] [Related]

  • 12. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
    Ukita T, Sugahara M, Terakawa Y, Kuroda T, Wada K, Nakata A, Ohmachi Y, Kikkawa H, Ikezawa K, Naito K.
    J Med Chem; 1999 Mar 25; 42(6):1088-99. PubMed ID: 10090791
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines.
    Moszczyński-Pętkowski R, Majer J, Borkowska M, Bojarski Ł, Janowska S, Matłoka M, Stefaniak F, Smuga D, Bazydło K, Dubiel K, Wieczorek M.
    Eur J Med Chem; 2018 Jul 15; 155():96-116. PubMed ID: 29870883
    [Abstract] [Full Text] [Related]

  • 14. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
    Kempson J, Pitts WJ, Barbosa J, Guo J, Omotoso O, Watson A, Stebbins K, Starling GC, Dodd JH, Barrish JC, Felix R, Fischer K.
    Bioorg Med Chem Lett; 2005 Apr 01; 15(7):1829-33. PubMed ID: 15780616
    [Abstract] [Full Text] [Related]

  • 15. 9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
    Bourguignon JJ, Désaubry L, Raboisson P, Wermuth CG, Lugnier C.
    J Med Chem; 1997 Jun 06; 40(12):1768-70. PubMed ID: 9191951
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate.
    O'Shea PD, Chen CY, Chen W, Dagneau P, Frey LF, Grabowski EJ, Marcantonio KM, Reamer RA, Tan L, Tillyer RD, Roy A, Wang X, Zhao D.
    J Org Chem; 2005 Apr 15; 70(8):3021-30. PubMed ID: 15822960
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.